SecBot SecBot
8-K ·Filed Nov 9, 2026

IBRX

ImmunityBio, Inc.
NEUTRAL
Impact 5/10
Horizonweeks Processed7d 16h ago SEC0001326110-26-000097
8-K Item 2.02: Earnings release
Actionable Insight • Neutral

Revenue miss vs consensus is notable but the FDA label expansion and positive BCG-naive trial data support a larger addressable market. Monitor Q4 revenue trajectory and the upcoming sBLA submission for BCG-naive NMIBC, which could significantly expand the patient population.

DirectionNeutral
Confidencehigh
Horizonweeks

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+5
Entry
$7.11
T+0 close · Nov 9, 2026 · via day close
Latest settled
−15.89%
T+5 · $5.98
Vs SPY
−14.20%
α at T+5
Next horizon
T+20
in 21d
  1. T+0 · Nov 9 $7.11entry
  2. T+1 · 7d ago −5.13%α −4.77% · $6.75
  3. T+5 · 17h ago −15.89%α −14.20% · $5.98
  4. T+20 · in 21d Pending
  5. T+60 · in 3mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

ImmunityBio reported Q3 2026 net product revenue of $48.7M, up 53% YoY, but missed consensus revenue estimates of $59.2M. The company also announced FDA label expansion for ANKTIVA in BCG-unresponsive NMIBC and positive Phase 2/3 data, while GAAP net loss widened to $184.6M driven by non-cash fair value changes. Cash and marketable securities stood at $334.3M.

Key Financial Metrics

EPS
−$0.17
Revenue
$48.7M
est $59.2M · -17.7% · +53.0% YoY

Key Facts

  • Q3 2026 net product revenue $48.7M, up 53% YoY from $31.8M
  • First nine months 2026 net product revenue $143.6M, up 92% YoY
  • Revenue miss: actual $48.7M vs consensus $59.2M
  • FDA expanded ANKTIVA label on Oct 14, 2026 to include papillary-only NMIBC
  • QUILT-2.005 trial in BCG-naive NMIBC met primary endpoint; sBLA submission on track for Q4 2026
  • ANKTIVA approved in Israel, first patients treated in Europe
  • GAAP net loss $184.6M vs $67.3M YoY, driven by non-cash fair value changes
  • Adjusted net loss $97.9M vs $72.4M YoY
  • Cash and marketable securities $334.3M as of Sep 30, 2026
  • Operating cash burn $75.3M in Q3 2026

Financial Impact

Q3 net product revenue $48.7M (missed consensus $59.2M by 17.7%); GAAP net loss $184.6M; adjusted net loss $97.9M; cash burn $75.3M

revenuenet losscash position

Risk Factors

  • Revenue miss of 17.7% vs consensus may pressure near-term sentiment
  • GAAP net loss widening due to non-cash fair value changes from stock price increase
  • Adjusted net loss also increased YoY, indicating rising operating costs
  • Cash burn of $75.3M per quarter; cash runway limited without additional financing or revenue acceleration
  • Dependence on continued ANKTIVA adoption and regulatory approvals

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
90% bullish (10 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001326110-26-000097
Document: ibrx-20261109.htm0001326110-26-000097
Document: 0001326110-26-000097-index-headers.html0001326110-26-000097
Document: 0001326110-26-000097-index.html0001326110-26-000097
Document: 0001326110-26-000097.txt0001326110-26-000097
8-K Data (Synthetic)0001326110-26-000097

Track record

11 reports on IBRX

Performance horizon

1 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +19.12% at T+60 after the Apr 9, 2026 report. 2 of 5 went positive at some point.

Filters
  1. Nov 9, 20267d ago 8-K Neutral 5/10 Viewing Entry $7.11 Now $5.98 −15.89% settles Feb 5
  2. Nov 9, 20267d ago 8-K Bullish 6/10 Entry $7.11 Now $5.98 −15.89% settles Feb 5
  3. Nov 4, 202612d ago Institutional Cluster Neutral 3/10 Entry $8.93 Now $5.98 −33.03% settles Feb 2
  4. Oct 14, 20264w ago 8-K Bullish 7/10 Entry $10.00 Now $5.98 −40.20% settles Jan 12
  5. Aug 4, 202614w ago 8-K Neutral 5/10 Entry $6.95 to $8.63 Now $5.98 −13.96% ▲ +24.17% +24.39% vs SPY
  6. Jul 6, 202619w ago Insider Cluster Neutral 2/10 Entry $8.76 to $9.44 Now $5.98 −31.74% ▲ +7.76% +5.77% vs SPY
  7. Jul 1, 202619w ago Insider Cluster Neutral 2/10 Entry $9.44 to $8.52 Now $5.98 −36.65% ▼ −9.75% −12.54% vs SPY
  8. May 18, 202626w ago 8-K Bullish 5/10 Entry $7.76 to $7.65 Now $5.98 −22.94% ▼ −1.42% −7.71% vs SPY
  9. Apr 9, 202631w ago 8-K Bullish 8/10 Entry $7.48 to $8.91 Now $5.98 −20.05% ▲ +19.12% +8.34% vs SPY
  10. Apr 6, 202632w ago 8-K Neutral 4/10 Entry $7.08 to $9.20 Now $5.98 −15.54% ▲ +29.94% +16.47% vs SPY
Showing 10 of 11

US Market Status

Market Closed · Opens Wed (9h 46m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 9, 2026